These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11526977)

  • 21. Synergistic interaction between mazindol, an anorectic drug, and swim-stress on analgesic responses in the formalin test in mice.
    Vendruscolo LF; Takahashi RN
    Neurosci Lett; 2004 Jan; 355(1-2):13-6. PubMed ID: 14729223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine.
    Calcagnetti DJ; Holtzman SG
    Pharmacol Biochem Behav; 1991 Jan; 38(1):185-90. PubMed ID: 2017444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia.
    Schäfer M; Imai Y; Uhl GR; Stein C
    Eur J Pharmacol; 1995 Jun; 279(2-3):165-9. PubMed ID: 7556397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A.
    Drinovac V; Bach-Rojecky L; Matak I; Lacković Z
    Neuropharmacology; 2013 Jul; 70():331-7. PubMed ID: 23499661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analgesic effect of corticotropin-releasing factor administered into midbrain periaqueductal grey matter].
    Iarushkina NI; Bagaeva TR; Filaretova LP
    Ross Fiziol Zh Im I M Sechenova; 2011 Dec; 97(12):1327-35. PubMed ID: 22384673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dopaminergic agents on visceral pain measured by the mouse writhing test.
    Frussa-Filho R; Rocha JB; Conceição IM; Mello CF; Pereira ME
    Arch Int Pharmacodyn Ther; 1996; 331(1):74-93. PubMed ID: 8896712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of nomifensine and imipramine on motivated behavior in the runway model of intracranial self-stimulation.
    Esumi S; Kawaski Y; Nakamoto A; Sagara H; Gomita Y; Kitamura Y; Sendo T
    Eur J Pharmacol; 2013 Nov; 720(1-3):186-191. PubMed ID: 24436978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethylketocyclazocine and bremazocine analgesia in neonatal rats.
    Helmstetter FJ; Calcagnetti DJ; Cramer CP; Fanselow MS
    Pharmacol Biochem Behav; 1988 Aug; 30(4):817-21. PubMed ID: 3067243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of kappa- and delta-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice.
    Reeta Kh; Mediratta PK; Rathi N; Jain H; Chugh C; Sharma KK
    Regul Pept; 2006 Jul; 135(1-2):85-90. PubMed ID: 16712978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone-induced analgesia: involvement of kappa-opiate receptors.
    Bianchi M; Panerai AE
    Pharmacol Biochem Behav; 1993 Sep; 46(1):145-8. PubMed ID: 8255904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analgesic properties of morpholinoethylimidazobenzimidazole derivative RU-1205].
    Spasov AA; Grechko OIu; Shtareva DM; Anisimova VA
    Eksp Klin Farmakol; 2013; 76(9):15-8. PubMed ID: 24432563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception.
    Gray AM; Nevinson MJ; Sewell RD
    Eur J Pharmacol; 1999 Jan; 365(2-3):149-57. PubMed ID: 9988097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. μ-Opioid and N-methyl-D-aspartate receptors in the amygdala contribute to minocycline-induced potentiation of morphine analgesia in rats.
    Ghazvini H; Rezayof A; Ghasemzadeh Z; Zarrindast MR
    Behav Pharmacol; 2015 Jun; 26(4):383-92. PubMed ID: 25563202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice.
    Corrêa CR; Kyle DJ; Chakraverty S; Calixto JB
    Br J Pharmacol; 1996 Feb; 117(3):552-558. PubMed ID: 8821548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute opioid pretreatment potentiates naltrexone-induced drinking suppression in water-deprived rats.
    White DA; Holtzman SG
    J Pharmacol Exp Ther; 2001 Jul; 298(1):156-64. PubMed ID: 11408537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.